trial

Oxytocin MEG Study

NCTId NCT02568709
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Early Phase 1 · Completed
Enrollment 40 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2016-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Early Phase 1
Status
Completed
Enrollment
40 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2012-02
Primary completion
2016-12
Eligibility
MALE · 18 Years · 40 Years

Interventions & indications

Drugs
Oxytocin

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor

Investigators

1
Josh D Woolley, MD/PhDPrincipal Investigator

Sites

1 total
San Francisco, United States

Facts & assertions

4 sourced
Enrollment
40
Phase
EARLY_PHASE1
Primary Completion Date
2016-12
Status
COMPLETED
relationships
The graph out of here
drug
Oxytocin
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
indication
Social Cognition
indication
Oxytocin
indication
Schizophrenia
indication
investigator
Josh D Woolley, MD/PhD
person